Business & Finance
CytRx reports $15.1 million net loss in 2005, recaps performance highlights
Published in Obesity and Diabetes Week, May 1st, 2006
"I am delighted to report that our achievements during the past year have brought us closer to our goal of commercializing human therapeutics based on our small molecule 'molecular chaperone' co-induction technology," said CytRx president and CEO Steven A. Kriegsman. "Most notable among our achievements in 2005 was the advancement of our orally-available small molecule drug candidate arimoclomol into Phase II development for the treatment of amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease.
"We also made excellent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity & Sleep Deprivation
Leptin deficiency disrupts the regulation of sleep architecture and diurnal rhythmicity - Obesity Epidemiology
ADRB2 gene accounts for obesity-related phenotypes in males - Obesity Pathogenesis
Adapter p62 is linked to mature-onset obesity and insulin resistance in mouse model - Obesity Therapy
Initial trocar placement is safe and effective in morbidly obese patients - Obesity Therapy
Selective 5-HT2C agonists show promise in obesity treatments - Angiogenesis
Data from angiogenesis program using cell labeling technology reported at conference - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
